Why IMU is a multi multi bagger, page-6034

There will always be competitors in the medical field and usually the drug which has shown to provide the most efficacy and safety is the treatment used by the majority, especially if you have backing of big pharmacies to navigate this political minefield and have patents to cover your IP, IMU currently has both.

But like other commercial treatment, there will be others used and we know this market is big enough to be captured by multiple treatments especially if CHECKvacc can be extended to not only target TNBC but also other cancer cells effectively which IMU says is possible, can the other treatment do this????

Sure, no competitor is a big positive if you can get the product first to commercial but I also see this as less chance the technology work so more risky until clinical prove to work and my point was more-so to give an explanation as why IMU's MC is currently 3x that of RAC due to more products further in the pipeline and market potential of these product. This is what investors take into account when investing biotech start-up hence the market has value them accordingly.